ArticleBMC psychiatry2026
Peripheral blood transcriptomic biomarkers for predicting antidepressant response in major depressive disorder.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) is a heterogeneous condition with substantial variability in antidepressant treatment response. Identifying predictive biomarkers could facilitate personalized treatment strategies and improve clinical outcomes.
methodsGene expression data from three cohorts (GSE146446, GSE45468, and GSE185855) were analyzed. Differential expression and weighted gene co-expression network analyses identified treatment response-associated modules. Hub genes from preserved modules underwent functional enrichment analysis. Boruta feature selection and Random Forest modeling were applied to derive a predictive gene panel. Model performance was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) metrics in discovery and validation cohorts.
resultsAn eight-gene panel (LAT, CLN5, LY96, IRAK4, ARPC2, CRB3, RAB13, and SLC25A42) was identified. These genes are involved in immune signaling, lysosomal and mitochondrial function, synaptic plasticity, and cellular transport. The Random Forest model achieved an AUC of 0.933 in the discovery cohort and AUCs of 0.683 and 0.677 in two validation cohorts.
conclusionThis study identified and validated a peripheral blood-based eight-gene expression signature predictive of antidepressant treatment response, supporting personalized treatment strategies for MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.